It has been shown that engineered T-cells constitutively expressing the IL-7 receptor alpha (IL-7Rα) have great antitumor efficacies in both breast cancer (136) and glioblastoma models (137), therefore, IL-7 and its receptor are great candidates for immunotherapy. This evidence concerns the gene IL7R and glioblastoma.